In Vivo Outlook 2024: A Health Care Metamorphosis

As we step into 2024, the healthcare and biopharma landscape faces the echoes of an unsteady geopolitical situation in eastern Europe, global inflation, and the politicization of drug pricing in the US that left their imprints on 2023. Predicting the future in the biopharma realm is inherently challenging, but glimpsing into the upcoming year suggests a surge in deal-making and the potential resurgence of larger-scale M&A activities. Big pharma, under pressure to fill pipeline gaps swiftly, may witness a transition year as companies navigate through lingering market turmoil.

Fresh growth areas for big pharma emerge in the realms of obesity and CNS diseases, with oncology reclaiming attention after being temporarily overshadowed by COVID-19 in the R&D setting. While technological advancements hold immense promise, they also introduce complexities regarding optimal applications. The rapid development of artificial intelligence tools outpaces the healthcare sector's adaptation speed.

Medtech companies face not only an unstable financial market but also increasing environmental demands. Simultaneously, healthcare systems grapple with the swift transformation of care delivery structures and the challenge of adjusting payment models to align with the growing shift towards ambulatory and home-based care.

The Outlook 2024 publication encompasses exclusive interviews, data, features, and industry league tables, including Scrip 100, Scrip Asia 100, Medtech 100, and Generics Bulletin’s Top 50, providing comprehensive insights into the evolving dynamics of the healthcare and biopharma sectors in the coming year.